Expert Review of Proteomics, published by TAYLOR & FRANCIS LTD, is a distinguished journal that focuses on the latest advancements in the field of proteomics, a critical area within biochemistry and molecular biology. With an ISSN of 1478-9450 and E-ISSN 1744-8387, this journal has been pivotal in disseminating high-quality research from its inception in 2004 to its planned convergence in 2024. Its influential position is reflected in its 2023 rankings, placing it in the Q2 category for both Biochemistry and Molecular Biology, alongside respectable Scopus rankings that rank it 118th and 141st in its respective categories. Despite its non-open access structure, Expert Review of Proteomics provides researchers and professionals with a vital platform for critical reviews and insights into proteomic methodologies, thus contributing significantly to the global scientific community. By bridging theoretical research with practical applications, it serves as an essential resource for those dedicated to advancing their knowledge and expertise in this dynamic field.

Current Proteomics is a distinguished journal dedicated to the dynamic field of proteomics, offering researchers and professionals a platform to disseminate innovative findings and comprehensive reviews. Published by Bentham Science Publishers Ltd, this journal caters to a global audience and serves as an essential resource for students, academics, and industry experts interested in advances in biochemistry and molecular biology. With an ISSN of 1570-1646 and an E-ISSN of 1875-6247, the journal has established itself in various research categories, achieving a Q4 ranking in both Biochemistry and Molecular Biology as of 2023. While the impact factor and H-index data are not specified, its Scopus ranking reflects a competitive position in its fields, with percentiles in the 12th to 16th range. Although not an open-access journal, Current Proteomics is vital for fostering ongoing dialogue and collaboration in proteomic research, encouraging contributions that explore cutting-edge methodologies and applications. Researchers are invited to share their insights and contribute to this evolving discipline, thus enhancing the collective understanding of proteomics within the scientific community.

Physiology and Pharmacology is a distinguished open access journal that has been disseminating high-quality research in the fields of physiology and pharmacology since its inception in 1997. Published by the Iranian Society of Physiology & Pharmacology, this journal offers a platform for scholars and practitioners to share innovative findings and advancements that contribute to the understanding of biological systems and drug action. With its ISSN 2476-5236 and E-ISSN 2476-5244, it ensures global reach and accessibility. The journal is positioned in the third quartile for Linguistics and Language and fourth quartile in both Pharmacology and Physiology categories according to Scopus rankings, reflecting a commitment to expanding knowledge within these interdisciplinary domains. Set within the academic landscape of Iran, the journal aims to bridge regional research with the international community, providing valuable insights into physiological processes and pharmacological developments. In light of its open access model, the Physiology and Pharmacology journal plays a crucial role in enhancing the visibility of research outcomes and fostering collaboration among researchers, professionals, and students on a global scale.

Molecular Omics is a premier, peer-reviewed journal published by the Royal Society of Chemistry, focusing on the interdisciplinary field of molecular biology with significant implications for biochemistry and genetics. With an E-ISSN of 2515-4184, this journal has been dedicated to disseminating high-quality research since its inception in 2018, maintaining an impressive trajectory in academic contributions until 2024. Currently, it holds a Q2 quartile ranking in both Biochemistry and Genetics, alongside a Q3 ranking in Molecular Biology for 2023, highlighting its relevance and influence in these domains. The journal is accessible as an open access publication, promoting the widespread dissemination of groundbreaking research. As part of a vibrant academic community, Molecular Omics aims to bridge fundamental and applied science, appealing to researchers, professionals, and students eager to expand their knowledge on molecular mechanisms and technologies that shape the future of biological research.

PROTEOMICS is a leading journal focused on the rapidly evolving field of proteomics, published by WILEY in Germany. With a solid reputation established since its inception in 2001, it has continually contributed to the understanding of protein functions and interactions within biological systems. As part of its commitment to academic excellence, PROTEOMICS is ranked in the second quartile for both Biochemistry and Molecular Biology categories (2023), reflecting its significant influence in advancing research in these areas. Although it does not currently provide open access options, it remains a vital resource for researchers, professionals, and students keen to explore innovative methodologies and findings in proteomic research. By publishing groundbreaking studies that bridge theoretical knowledge with practical applications, PROTEOMICS plays a crucial role in enhancing our understanding of molecular processes and driving forward advancements in the life sciences.

AMYLOID - JOURNAL OF PROTEIN FOLDING DISORDERS, published by Taylor & Francis Ltd, is a premier academic journal dedicated to the crucial field of protein folding disorders, offering a vital platform for researchers and healthcare professionals. With an impressive impact factor and classified in the Q1 quartile across both Internal Medicine and Miscellaneous Medicine categories, this journal ranks within the top 15% of its field according to Scopus, with a remarkable rank of #18 out of 167. Covering interdisciplinary approaches that intersect molecular biology, neuroscience, and clinical implications of amyloidosis and related disorders, AMYLOID encourages the dissemination of innovative research findings from 1994 to 2024 and beyond. Despite lacking Open Access options, the journal remains a significant resource for advancing the understanding of protein misfolding diseases, influencing clinical practice and therapeutic developments. With its longstanding commitment to high-quality research, AMYLOID continues to be an essential reading for scholars, practitioners, and students who aim to make significant contributions to this evolving field.

MASS SPECTROMETRY REVIEWS, published by Wiley, is a premier academic journal dedicated to advancing the field of mass spectrometry and its applications across a multitude of scientific disciplines. With an ISSN of 0277-7037 and an E-ISSN of 1098-2787, the journal has established itself as a vital resource within the realms of Analytical Chemistry, Biochemistry, Genetics, Condensed Matter Physics, and Spectroscopy, achieving Q1 status across these categories in 2023. As a testament to its significant contribution to scholarly research, it boasts impressive Scopus rankings, including a rank of #2 out of 76 in Chemistry - Spectroscopy and #4 out of 156 in Chemistry - Analytical Chemistry, placing it in the 97th percentile and above. Emphasizing high-quality, peer-reviewed research, MASS SPECTROMETRY REVIEWS serves as an essential platform for researchers, professionals, and students aiming to stay abreast of cutting-edge developments and methodologies in mass spectrometry. The journal is committed to fostering a deeper understanding of mass spectrometric techniques while also contributing to interdisciplinary advancements, making it a valuable addition to any academic library. Authors seeking to disseminate their work in a journal with a strong reputation and impact in the scientific community will find MASS SPECTROMETRY REVIEWS an ideal venue.

Journal of Proteomics, published by Elsevier, is an esteemed peer-reviewed journal dedicated to advancing research in the field of proteomics, with broad implications for biochemistry and biophysics. Established in 2008, the journal has continuously evolved, embracing innovative methodologies and technologies that facilitate protein analysis from a variety of biological systems. With its current standing in the Q2 category for both biochemistry and biophysics as of 2023, it is recognized as a significant contributor to scientific literature. The journal publishes original research articles, reviews, and methodological advancements, providing invaluable insights for researchers, professionals, and students alike. Although it does not offer open access, the journal remains a crucial platform for disseminating knowledge that informs various applications, ranging from drug development to disease understanding. As it converges towards 2024, the Journal of Proteomics continues to solidify its role in shaping the future of proteomic research through rigorous scientific inquiry and innovation.

Proteomes, published by MDPI since 2013, is a notable open access journal that occupies a critical place in the realms of Biochemistry, Clinical Biochemistry, Molecular Biology, and Structural Biology. Based in Switzerland, this journal not only promotes the dissemination of high-quality research pertaining to protein structures and functions but also emphasizes interdisciplinary approaches that bridge various fields of biomedical science. With a Category Quartile ranking of Q2 across multiple pertinent categories in 2023, Proteomes boasts a competitive impact within the scientific community, evidenced by its robust Scopus rankings. Researchers, professionals, and students are invited to explore a wealth of pioneering studies and reviews that are made freely accessible, aligning with global trends in open scientific communication. Whether contributing original research or seeking to expand their knowledge, the journal serves as an invaluable resource for anyone engaged in the evolving landscape of proteomics.

Biomarker Insights, published by SAGE Publications Ltd, is a leading open-access journal dedicated to advancing the field of biomarker research and its applications in health and disease. With an ISSN of 1177-2719 and an E-ISSN of 1177-2719, this journal has been at the forefront of disseminating high-quality scientific findings since its inception in 2006. Based in New Zealand, it has achieved a notable impact within the academic community, ranking in Q2 for Biochemistry (medical) and Molecular Medicine, and Q1 in Pharmacology as of 2023. This positions Biomarker Insights as a critical resource for researchers, professionals, and students alike, looking to explore innovative methodologies and applications in biomarker discovery and validation. With a commitment to open access, the journal ensures that groundbreaking research is readily available to the global community, fostering collaboration and innovation in the ever-evolving field of biomedical sciences.